Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.
The phase 3 CLEAR study (NCT02811861) compared 3 treatments for advanced renal cell carcinoma: lenvatinib (Lenvima) plus pembrolizumab (Keytruda), lenvatinib plus everolimus, and sunitinib (Sutent). Lenvatinib plus pembrolizumab demonstrated significantly longer progression-free survival and overall survival.
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, investigators presented data from a biomarker analysis of the CLEAR trial. This study investigated potential markers to predict treatment response.
The lenvatinib and pembrolizumab combination remained more effective than sunitinib regardless of the tested markers, including gene expression signatures related to cell growth, blood vessel formation, and immune response. In the lenvatinib and pembrolizumab arm, PD-L1 status wasn't linked to treatment response. However, a signature associated with MYC was linked to poorer response. the inflamed immune state signature was linked to better response, and a signature related to blood vessel formation was also linked to better response. Standard markers like PD-L1 expression and mutation rates in specific genes weren't linked to treatment response in either arm.
Overall, these findings suggest that the lenvatinib and pembrolizumab combination may be broadly effective across different genetic profiles in advanced RCC and these specific markers may not be helpful for selecting patients for this treatment.
Here, Jaime Merchan, MD, professor, co-leader of the Translational and Clinical Oncology Research Program, and director of the Phase 1 Clinical Trials Program at the Sylvester Comprehensive Cancer Center at the University of Miami, discusses findings from this analysis presented at the 2024 ASCO Meeting.
Transcription:
0:05 | This study was a biomarker analysis of the CLEAR trial trying to determine a correlation between a progression-free survival in the pembrolizumab and lenvatinib versus sunitinib group in correlation with different biomarkers including PD-L1 expression, gene expression signatures, and also genomic abnormalities.
0:28 | The results of the study showed that regardless of any biomarkers, the combination of pembrolizumab and lenvatinib was superior or associated with a better median progression-free survival compared to sunitinib in both expression of PD-L1, different dynamic signatures or gene expression analysis, and also a genomic alterations, specifically mutations of the common renal cell carcinoma gene alterations. The study showed no clear correlation of any benefit with any of these biomarkers.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More